Aditxt, Inc. /
Evofem
Aditxt to merge with Evofem Biosciences
Source for the buyer and target: Evofem Biosciences, Inc.
For the buyer and target.
“Holders of Evofem common stock, Series E-1 Convertible Preferred Stock, and Series G-1 Convertible Preferred Stock will be asked to approve the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended (the “Merger Agreement”), by and among Aditxt, Inc. a Delaware corporation (“Aditxt”), Adifem, Inc., a Delaware corporation and a wholly owned Subsidiary of Aditxt, (“Merger Sub”), pursuant to which the Merger Sub, will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Aditxt (the “Merger”).”
Published 8 Sep 2025
Open the sourceWhat happened
Aditxt, Inc. and Evofem Biosciences, Inc. are parties to a merger agreement under which Evofem would become a wholly owned subsidiary of Aditxt. The filing describes the merger as subject to stockholder approval. [01]
The common stock consideration is an aggregate amount of $1,800,000, subject to adjustments described in the filing. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Aditxt to merge with Evofem Biosciences
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly